Pendopharm, a division of Pharmascience Inc., announced today that Health Canada has granted market authorization for Yorvipath® (palopegteriparatide injection), a parathyroid hormone (PTH) replacement therapy indicated for the treatment of chronic hypoparathyroidism in adults. Yorvipath®, was developed by Ascendis Pharma A/S (NASDAQ:ASND) ("Ascendis").

This approval follows the exclusive distribution agreement signed in July 2024 between Pendopharm and Ascendis Pharma, under which Pendopharm is responsible for the regulatory approval and commercialization of Yorvipath® in Canada, which is already approved in the US, European Union, UK, Australia, Switzerland, Israel and Japan. It is also under regulatory review or in development in other global markets.

Pendopharm is collaborating closely with key partners to support a smooth transition toward market availability and to support efforts aimed at achieving coverage through public and private drug plans.

• No comments yet. Be the first to comment!